Rapport Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Sofinnova Venture Partners XI and related entities, including Dr. James I. Healy, reported a decrease in their beneficial ownership of Rapport Therapeutics, Inc. common stock to below 5% due to dilution from the Issuer's recent share sales.